中国科学院生物与化学交叉研究中心

设为首页 中文版

研究团队

您的位置:首页 > 研究团队 > 谭立课题组
发表文章

代表论文:

(1) Hai-Tsang Huang, DennisDobrovolsky, Joshiawa Paulk, Guang Yang, Ellen L. Weisberg, Zainab M. Doctor,Dennis L. Buckley, Joong-Heui Cho, Eunhwa Ko, Jaebong Jang, Kun Shi, Hwan GeunChoi, James D. Griffin, Ying Li, Steven P. Treon, Eric S. Fischer, James E.Bradner, Li Tan*, Nathanael S. Gray*, AChemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinaseDegrader, Cell Chemical Biology, 2018, 25(1):88-99

(2) Li Tan#, Jun Wang#, Junko Tanizaki#,Zhifeng Huang#, Amir R. Aref#, Maria Rusan, Su-Jie Zhu, YiyunZhang, Dalia Ercan, Rachel G. Liao, Marzia Capelletti, Wenjun Zhou, WooyoungHur, NamDoo Kim, Taebo Sim, Suzanne Gaudet, David A. Barbie, Jing-Ruey JoannaYeh, Cai-Hong Yun, Peter S. Hammerman*, Moosa Mohammadi*,Pasi A. Jänne*, Nathanael S. Gray*, Development ofcovalent inhibitors that can overcome resistance to first-generation FGFRkinase inhibitors, Proceedings of the National Academy of Sciences of theUnited States of America, 2014, 111(45):E4869-4877

(3) Li Tan#, Koshi Akahane#, Randall McNally, Kathleen M. S. E. Reyskens, Scott B. Ficarro, Suhu Liu, Grit S. Herter-Sprie, Shohei Koyama, Michael J. Pattison, Katherine Labella, Liv Johannessen, Esra A. Akbay, Kwok-Kin Wong, David A. Frank, Jarrod A. Marto, Thomas A. Look, J. Simon C. Arthur, Michael J. Eck, Nathanael S. Gray*,Development of Selective Covalent Janus Kinase 3 Inhibitors, Journal ofMedicinal Chemistry, 2015, 58(16):6589-6606

(4) Li Tan, TyzoonNomanbhoy, Deepak Gurbani, Matthew Patricelli, John Hunter, Jiefei Geng, LinaHerhaus, Jianming Zhang, Eduardo Pauls, Youngjin Ham, Hwan Geun Choi, Ting Xie,Xianming Deng, Sara J. Buhrlage, Taebo Sim, Philip Cohen, Gopal Sapkota, KennethD. Westover, Nathanael S. Gray*, Discovery of type II inhibitors ofTGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinasekinase kinase 2 (MAP4K2), Journal of Medicinal Chemistry, 2015, 58(1):183-196

(5) Hideki Terai#, Li Tan#, Ellen M. Beauchamp, John M. Hatcher, QingsongLiu, Matthew Meyerson, Nathanael S. Gray*, Peter S. Hammerman*,Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated NonsmallCell Lung Cancer, ACS Chemical Biology, 2015, 10 (12):2687-2696

(6) Zhifeng Huang#, Li Tan#, Huiyan Wang#, Yang Liu, Steven Blais,Jingjing Deng, Thomas A. Neubert, Nathanael S. Gray, Xiaokun Li*, MoosaMohammadi*, DFG-out mode of inhibition by an irreversible type-1inhibitor capable of overcoming gate-keeper mutations in FGF receptors, ACSChemical Biology, 2015, 10(1):299-309

(7) Hyung-Gu Kim#, Li Tan#, Ellen L. Weisberg#, Feiyang Liu#,Peter Canning#, Hwan Geun Choi#, Scott A. Ezell, Hong Wu,Zheng Zhao, Jinhua Wang, Anna Mandinova, James D. Griffin, Alex N. Bullock,Qingsong Liu*, Sam W. Lee*, Nathanael S. Gray*,Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor, ACSChemical Biology, 2013, 8(10):2145-2150

(8) Li Tan#, DeepakGurbani#, Ellen L. Weisberg, John C. Hunter, Lianbo Li, Douglas S.Jones, Scott B. Ficarro, Samar Mowafy, Chun-Pong Tam, Suman Rao, Guangyan Du, JamesD. Griffin, Peter K. Sorger, Jarrod A. Marto, Kenneth D. Westover*, NathanaelS. Gray*, Structure-guideddevelopment of covalent TAK1 inhibitors, Bioorganic Medicinal Chemistry, 2017,25(3):838-846

(9) Li Tan#, Deepak Gurbani#, Ellen L. Weisberg#,Douglas S. Jones#, Suman Rao, William D. Singer, Faviola M. Bernard,Samar Mowafy, Annie Jenney, Guangyan Du, Atsushi Nonami, James D. Griffin, DouglasA. Lauffenburger, Kenneth D. Westover*, Peter K. Sorger*,Nathanael S. Gray*, Studies of TAK1-centered polypharmacology withnovel covalent TAK1 inhibitors, Bioorganic Medicinal Chemistry, 2017,25(4):1320-1328

(10) Li Tan, Dawei Ma, Totalsynthesis of salinamide A: a potent anti-inflammatory bicyclic depsipeptide, AngewandteChemie International Edition, 2008, 47(19):3614-3617

申请专利:

1.     GrayNS and Tan L. JANUS KINASE INHIBITORS AND USESTHEREOF. WO/2015/164614.

2.     GrayNS and Tan L. HYDROPHOBICALLY TAGGED JANUS KINASE INHIBITORS AND USESTHEREOF. WO/2015/164604.

3.     Treon SP, Gray NS, Buhrlage SJ, Tan L and Yang G. METHODS TO TREAT LYMPHOPLASMACYTICLYMPHOMA. WO/2015/089479.

4.     Treon SP, Gray NS, Buhrlage SJ, Tan L and Yang G. METHODS TO TREAT LYMPHOPLASMACYTICLYMPHOMA. WO/2015/089481.

5.     Gray NS, Choi HG and Tan L. KINASE INHIBITORS FOR THE TREATMENTOF DISEASE. WO/2015/006492.

6      TreonSP, Yang G, Gray NS, Buhrlage SJ and TanL. HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES. PCT15/581,736

7. GrayNS, Tan L, Huang H-T, Bradner JE,Buckley D, Winter G, and Ishoey M. DEGRADATION OF PROTEIN KINASES BYCONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OFUSE. Provisional application No. 62/420,136.

 


中国科学院生物与化学交叉研究中心 版权所有 电话:021-54925106/50800885
地址:上海市徐汇区零陵路345号君谋楼/浦东张江高科技园区秋月路26号6号楼 技术支持:FLAT